Myeloid dendritic cells type 2 after allergen inhalation in asthmatic subjects

Authors

  • B. Dua,

    1. Firestone Institute of Respiratory Health, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    Search for more papers by this author
  • W. Tang,

    1. Firestone Institute of Respiratory Health, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    Search for more papers by this author
  • R. Watson,

    1. Firestone Institute of Respiratory Health, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    Search for more papers by this author
  • G. Gauvreau,

    1. Firestone Institute of Respiratory Health, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    Search for more papers by this author
  • P. M. O'Byrne

    Corresponding author
    1. Firestone Institute of Respiratory Health, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
    • Correspondence:

      Paul M. O'Byrne, Rm 3W10, McMaster University Medical Center, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada.

      E-mail: obyrnep@mcmaster.ca

    Search for more papers by this author

Summary

Background

Dendritic cells (DCs) are professional antigen-presenting cells that mediate the response to inhaled allergen. A major division in DC ontogeny exists between myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). A subtype of mDC expressing thrombomodulin, termed myeloid DCs type 2 (mDC2s), has been identified in both the circulation and lung and has recently been suggested to have a role in allergic asthma.

Objective

To investigate changes in circulating and sputum mDC2s after allergen inhalation in subjects with asthma.

Methods

Peripheral blood and induced sputum were obtained before and 3, 7, and 24 h after inhalation of diluent and allergen from allergic asthmatic subjects who develop both allergen-induced early- and late-phase responses. mDC2s were measured by flow cytometry. Soluble BDCA-3 (thrombomodulin) was measured in sputum by ELISA.

Results

The number of sputum mDC2s significantly increased 24 h after allergen challenge compared with diluent. The expression of BDCA-3 on sputum mDCs also increased, albeit non-significantly, at 7 and 24 h after allergen. Soluble BDCA-3 in sputum and the number of circulating mDC2s were not different between allergen and diluent.

Conclusions and clinical relevance

Myeloid DCs type 2 (mDC2s) increase in the sputum of subjects with asthma after allergen challenge, suggesting this subtype of mDC is involved in the regulation of allergen responses in the lung.

Ancillary